SARC Clinical Trials

A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

TYPE OF SARCOMA: Soft Tissue Sarcoma of the Extremity
DRUG: Pembrolizumab
ACCRUAL STATUS: Recruiting

A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3’-Deoxy-3’-18F Fluorothymidine (18F-FLT) Imaging

TYPE OF SARCOMA: Ewing Sarcoma
DRUG: Trabectedin and Irinotecan
ACCRUAL STATUS: Recruiting

A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma

TYPE OF SARCOMA: Epithelioid Hemangioendothelioma
DRUG: Trametinib
ACCRUAL STATUS: Not recruiting

A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors

TYPE OF SARCOMA: Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)
DRUG: Selumetinib in Combination with Sirolimus
ACCRUAL STATUS: Recruiting

A phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas

TYPE OF SARCOMA: Undifferentiated Pleomorphic Sarcoma and Poorly Differentiated/Dedifferentiated Liposarcoma
DRUG: Pembrolizumab
ACCRUAL STATUS: Not Recruiting

A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

TYPE OF SARCOMA: Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma
DRUG: Regorafenib
ACCRUAL STATUS: Recruiting